Erratum: Corrigendum to “In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2” (Lung Cancer (2006) 53(3) (273–284) (S0169500206003308) (10.1016/j.lungcan.2006.06.006));In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2

Lung Cancer

Volumn 53, Issue 3, 2006, Pages 273-284

  Finan, Katherine M ^a   Hodge, Greg ^a,b,c   Reynolds, Ann M ^a   Hodge, Sandra ^a   Holmes, Mark D ^a,c   Baker, Andrew H ^d   Reynolds, Paul N ^a,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

A549 lung cancer cell line; Apoptosis; Gene therapy; Lung cancer; Subcutaneous lung cancer nodules; TIMP 3

Indexed keywords

ADENOVIRUS VECTOR; FAS LIGAND; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; EMBRYO; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LUNG CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; TUMOR CELL DESTRUCTION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 33746902022     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.002     Document Type: Erratum

References (55)

1. Fong K.M., Sekido Y., Gazdar A.F., and Minna J.D. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 58 10 (2003) 892-900
2. American Cancer Society. Cancer facts and figures (2005), American Cancer Society, Atlanta
3. Kahari V.M., and Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31 1 (1999) 34-45
4. Chambers A.F., and Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89 17 (1997) 1260-1270
5. Baker A.H., Zaltsman A.B., George S.J., and Newby A.C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 101 6 (1998) 1478-1487
6. Zucker S., Cao J., and Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19 56 (2000) 6642-6650
7. Bachman K.E., Herman J.G., Corn P.G., Merlo A., Costello J.F., Cavenee W.K., et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59 4 (1999) 798-802
8. Yu W.H., Yu S., Meng Q., Brew K., and Woessner Jr. J.F. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 275 40 (2000) 31226-31232
9. Qi J.H., Ebrahem Q., Moore N., Murphy G., Claesson-Welsh L., Bond M., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9 4 (2003) 407-415
10. Amour A., Slocombe P.M., Webster A., Butler M., Knight C.G., Smith B.J., et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435 1 (1998) 39-44
11. Edwards D.R. TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges. J Pathol 202 4 (2004) 391-394
12. Ahonen M., Baker A.H., and Kahari V.M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 58 11 (1998) 2310-2315
13. Kashiwagi M., Tortorella M., Nagase H., and Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 276 16 (2001) 12501-12504
14. Smith M.R., Kung H., Durum S.K., Colburn N.H., and Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 9 10 (1997) 770-780
15. Fitzgerald M.L., Wang Z., Park P.W., Murphy G., and Bernfield M. Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148 4 (2000) 811-824
16. Rigg A.S., and Lemoine N.R. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 8 11 (2001) 869-878
17. Lamfers M.L., Gianni D., Tung C.H., Idema S., Schagen F.H., Carette J.E., et al. Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res 65 20 (2005) 9398-9405
18. Baker A.H., George S.J., Zaltsman A.B., Murphy G., and Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 79 9-10 (1999) 1347-1355
19. Reynolds P.N., Nicklin S.A., Kaliberova L., Boatman B.G., Grizzle W.E., Balyasnikova I.V., et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 19 9 (2001) 838-842
20. Hodge G., Hodge S., and Han P. Increased levels of apoptosis of leukocyte subsets in cultured PBMCs compared to whole blood as shown by Annexin V binding: relevance to cytokine production. Cytokine 12 12 (2000) 1763-1768
21. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101 6 (2003) 2125-2131
22. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 4 (2001) 487-501
23. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 6 (2000) 599-609
24. Vandenabeele P., Declercq W., Vanhaesebroeck B., Grooten J., and Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol 154 6 (1995) 2904-2913
25. Haridas V., Darnay B.G., Natarajan K., Heller R., and Aggarwal B.B. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 160 7 (1998) 3152-3162
26. Knox P.G., Milner A.E., Green N.K., Eliopoulos A.G., and Young L.S. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 170 2 (2003) 677-685
27. Knox P.G., Milner A.E., Green N.K., Eliopoulos A.G., and Young L.S. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand. J Immunol 170 2 (2003) 677-685
28. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., et al. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 26 7 (2006) 2782-2790
29. Bond M., Murphy G., Bennett M.R., Newby A.C., and Baker A.H. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 277 16 (2002) 13787-13795
30. Cox G., Steward W.P., and O'Byrne K.J. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 54 2 (1999) 169-179
31. Schutz A., Schneidenbach D., Aust G., Tannapfel A., Steinert M., and Wittekind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 23 3 (2002) 179-184
32. Guedez L., Stetler-Stevenson W.G., Wolff L., Wang J., Fukushima P., Mansoor A., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102 11 (1998) 2002-2010
33. Brand K., Baker A.H., Perez-Canto A., Possling A., Sacharjat M., Geheeb M., et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60 20 (2000) 5723-5730
34. Valente P., Fassina G., Melchiori A., Masiello L., Cilli M., Vacca A., et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 75 2 (1998) 246-253
35. Wang M., Liu Y.E., Greene J., Sheng S., Fuchs A., Rosen E.M., et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 14 23 (1997) 2767-2774
36. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 5381 (1998) 1305-1308
37. Wajant H. The Fas signaling pathway: more than a paradigm. Science 296 5573 (2002) 1635-1636
38. Itoh N., and Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268 15 (1993) 10932-10937
39. Timmer T., de Vries E.G., and de Jong S. Fas receptor-mediated apoptosis: a clinical application?. J Pathol 196 2 (2002) 125-134
40. Heller R.A., Song K., Fan N., and Chang D.J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70 1 (1992) 47-56
41. Kelliher M.A., Grimm S., Ishida Y., Kuo F., Stanger B.Z., and Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8 3 (1998) 297-303
42. Ahonen M., Poukkula M., Baker A.H., Kashiwagi M., Nagase H., Eriksson J.E., et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 22 14 (2003) 2121-2134
43. Belotti D., Paganoni P., and Giavazzi R. MMP inhibitors: experimental and clinical studies. Int J Biol Markers 14 4 (1999) 232-238
44. Bergers G., Javaherian K., Lo K.M., Folkman J., and Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284 5415 (1999) 808-812
45. Bloomston M., Shafii A., Zervos E.E., and Rosemurgy A.S. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 102 1 (2002) 39-44
46. Akahane T., Akahane M., Shah A., Connor C.M., and Thorgeirsson U.P. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res 301 2 (2004) 158-167
47. Hornebeck W., Lambert E., Petitfrere E., and Bernard P. Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression. Biochimie 87 3-4 (2005) 377-383
48. Ikenaka Y., Yoshiji H., Kuriyama S., Yoshii J., Noguchi R., Tsujinoue H., et al. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 105 3 (2003) 340-346
49. Feldman A.L., Stetler-Stevenson W.G., Costouros N.G., Knezevic V., Baibakov G., Alexander Jr. H.R., et al. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. Cancer Res 64 13 (2004) 4481-4486
50. Stetler-Stevenson W.G., and Seo D.W. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 11 3 (2005) 97-103
51. Anand-Apte B., Pepper M.S., Voest E., Montesano R., Olsen B., Murphy G., et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 38 5 (1997) 817-823
52. Spurbeck W.W., Ng C.Y., Strom T.S., Vanin E.F., and Davidoff A.M. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 100 9 (2002) 3361-3368
53. Yu X.F., Yang C., Liang L.H., Liu B., Zhou B., Li B., et al. Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3. Leukemia 20 1 (2006) 1-8
54. Apte S.S., Olsen B.R., and Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270 24 (1995) 14313-14318
55. Leco K.J., Khokha R., Pavloff N., Hawkes S.P., and Edwards D.R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269 12 (1994) 9352-9360